会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明授权
    • Humanized FcγRIIB-specific antibodies and methods of use thereof
    • 人源化FcγRIIB特异性抗体及其使用方法
    • US07786270B2
    • 2010-08-31
    • US11754015
    • 2007-05-25
    • Leslie S. JohnsonLing Huang
    • Leslie S. JohnsonLing Huang
    • C12P21/08
    • A61K39/39A61K2039/505A61K2039/55516C07K16/283C07K2317/24C07K2317/34C07K2317/52G01N33/564G01N33/6893G01N2800/24
    • The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
    • 本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体,其片段和变体。 本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病(例如癌症,自身免疫性和炎症性疾病)的用途。 本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。 本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。 本发明包括治疗自身免疫性疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。
    • 46. 发明申请
    • LARGE-FIELD UNIT-MAGNIFICATION PROJECTION OPTICAL SYSTEM
    • 大型放大投影光学系统
    • US20090185290A1
    • 2009-07-23
    • US12302824
    • 2006-12-04
    • Tiejun LiLing HuangJun Wei
    • Tiejun LiLing HuangJun Wei
    • G02B17/08
    • G02B17/08G02B13/26G03F7/70225G03F7/70791
    • The present invention discloses a large-field unit-magnification projection optical system. The optical system includes an optical axis, a spherical concave reflection mirror; a lens group with positive refracting power arranged adjacent the mirror with an air space therebetween. The lens group includes a first plano-convex lens, a negative meniscus lens adjacent the plano-convex lens, a positive lens adjacent the negative meniscus lens, a negative double-convex lens spaced apart far from the positive lens, and a second plano-convex lens. The optical system further includes a pair of prisms each having respective first and second surface. The second surfaces are arranged adjacent the flat surface of the plano-convex lens element on opposite sides of the optical axis and the first surfaces are arranged adjacent object planes and image planes, respectively. Each lens in the lens group and the pair of prisms provide chromatic aberration correction in a spectral region that contains at least g, h and i-line wavelengths. In this projection optical system, the object plane is parallel to the image plane.
    • 本发明公开了一种大视场单位放大投影光学系统。 光学系统包括光轴,球面凹面反射镜; 具有正反射功率的透镜组,其布置在反射镜附近,其间具有空气空间。 透镜组包括第一平凸透镜,与平凸透镜相邻的负弯月透镜,邻近负弯月透镜的正透镜,与正透镜间隔开的负双凸透镜,以及第二平凸透镜, 凸透镜 光学系统还包括一对棱镜,每个棱镜具有相应的第一和第二表面。 第二面与光轴的相对侧的平凸透镜元件的平面相邻配置,第一面与物平面和像面分别配置。 透镜组中的每个透镜和一对棱镜在包含至少g,h和i线波长的光谱区域中提供色差校正。 在该投影光学系统中,物平面与图像平面平行。
    • 48. 发明申请
    • Covalent diabodies and uses thereof
    • 共价双抗体及其用途
    • US20070004909A1
    • 2007-01-04
    • US11409339
    • 2006-04-17
    • Leslie JohnsonLing Huang
    • Leslie JohnsonLing Huang
    • C07K16/30
    • C07K16/283A61K2039/505C07K16/08C07K16/12C07K16/30C07K16/44C07K2317/24C07K2317/31C07K2317/34C07K2317/52C07K2317/53C07K2317/622C07K2317/626
    • The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    • 本发明涉及双抗体分子及其在治疗各种疾病和病症(包括免疫学疾病,感染性疾病,中毒和癌症)中的用途。 本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链,其可识别相同或不同抗原上相同或不同的表位。 另外,抗原可以来自相同或不同的分子。 双抗体分子的单个多肽链可以通过非肽键共价键共价结合,例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。 在具体实施方案中,本发明的双抗体分子还包含Fc区,其允许抗体样功能被改造成分子。